TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety of chronic administration of raloxifene
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with three or more spontaneous, complete bowel movements per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vessel density in retinal choriocapillaris networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative damage change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pro-inflammatory cytokines change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Comfortable Gait Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in intermediate phenotypes of atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With First-Cycle Dose-Limiting Toxicitys (DLTs) by Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Hemoglobin (Hgb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in Red Blood Cell (RBC) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Raltegravir Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raltegravir AUC12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UK-453,061 Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UK-453,061 AUC24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time when the foot is flat on the ground during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinical treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CHWs appropriately managing chest indrawing pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Travel
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Missed school/work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Out of pocket cost
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Abstinence for 7 consecutive days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of excess arm volume from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: u-AQP-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: FeNa+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of cerebral blood flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients presenting significant ophthalmologic pathologies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of complete and partial responses (CR/PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival and leukemia free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Who Complete the Post-vaccination Pain Assessment at 1 Minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Complete the Post-vaccination Anxiety Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects Who Complete the Pre-vaccination Needle Phobia Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Liver disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Probability of Having Utility Function Greater Than 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change From Baseline in Karolinska Sleepiness Scale (KSS) Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Investigator's Global Assessment of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive Performances
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: response to hypoxia test (peripheral chemoreceptor activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: narcotic consumption after surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in FLACC Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Seizure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With High Adherence to Dabigatran Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration Versus Time Curve (AUClast) of Oseltamivir and Oseltamivir Carboxylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Oseltamivir and Oseltamivir Carboxylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Bacterial uptake in the duodenal biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Post-concussion Symptom Scores Using RPQ
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stepping-up to higher intensity services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Histopathological changes in tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in empathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in geriatric attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in embodiment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time of Foley catheter extrusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of Acute Gastrointestinal and Genitourinary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: tissue levels of HIF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue levels of VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue levels of angiostatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in total PANSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days to union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: local and regional lymphnode control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: free-recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Average overground 360 degree turning speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desire domain score in the Female Sexual Function Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Item 13 score in the Female Sexual Distress Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: LP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fructose levels in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Severe disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain - VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain - PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in client Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient activation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of patient rated pain on NRS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parental distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parental self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in child emotional and behavioral problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-time target rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate of Sintilimab and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the combination therapy of Sintilimab and Metformin
Endpoint domain: Adverse events/effects
Primary endpoint: influence of nitrous oxide on the automated administration of propofol and remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood oxygenation of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in Gait Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in UPDRS Part III on/off stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Pain associated with injection of lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Prespecified Primary Safety Events Within 30 Days of Index Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Vigilance during prolonged wakefulness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood oxygen level dependent response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of solid cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Volar angulation of distal radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 14-item Hamilton Anxiety Rating Scale (HAM-A) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving 4-fold or greater hemagglutination inhibition (HAI) antibody titer increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Aortic valve perivalvular leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional grip strength change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence free survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Change in Tinnitus Functional Index (TFI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient follow up time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily dose of REKOVELLE administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Duration of treatment with REKOVELLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Duration of treatment with GnRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Evaluable Participants Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment Percentage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Placebo Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Tau protein in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Signs and symptoms outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Prematurely Withdrawn From Maintenance Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 90-day urinary tract infection (UTI) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in health related quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of culture-proven sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Atrial fibrillation (AF)/Atrial tachycardia (AT) recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Masticatory muscle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum triglycerides level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum Hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain intensity at injection site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Left Ventricular Assist Device Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Functionality of immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Use of Any the Patient Gateway Portal at 3 Months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Scores of Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ocular Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serious Adverse Reactions related to Cystadrops
Endpoint domain: Adverse events/effects
Primary endpoint: All Adverse Events that required discontinuation/withdrawal of IMP
Endpoint domain: Adverse events/effects
Primary endpoint: Non-fasting Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-fasting Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median time to discontinuation (mTTD)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of treatment related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of dose reduction and temporary or definitive treatment interruption due to AE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Over Ground Gait Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dynamic Mobility Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-effectiveness of intervention programs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients with severe mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Progression-free survival (PFS) at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: American Urological Association symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delivery mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite neonatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of signal void on MRI scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point Prevalence Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient knowledge about pacemakers and ICDs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite of Death and Recurrence Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of infusion phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in 24-hour Pain Intensity Ratings Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalogram (EEG) data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participants Achieving the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risk of Posthepatectomy Liver Failure (PHLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of screw replacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: stair climb test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: timed Up and Go test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS(Visual Analog Scale score) for knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Knee injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived Competence Scale (PCS) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the severity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodic limb movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroke or Death
Endpoint domain: Mortality/survival
Primary endpoint: Aneurysm Occlusion of the Treated Target Lesion on 12 Month Angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Functional Independence Measure (FIM) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in morning blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in classification of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Died During Index Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Died Within the 30 Days After Hospital Discharge (Including In-Hospital Mortality)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Died Within 60 Days After Hospital Discharge (Including In-Hospital Mortality)
Endpoint domain: Mortality/survival
Primary endpoint: Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode
Endpoint domain: Adverse events/effects
Primary endpoint: Severe oral mucositis (grade 3-4)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients That Develop Ocular GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of liver function measured by change in MELD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of the Child-Safety Plan Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the Child-Safety Plan Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Xerostomia Questionnaire Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hour glucose profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of CTP-656 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reducing Microbiological Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Breast Cancer specific Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Major Cardiac Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of ZIKV DNA vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Luteinizing Hormone (LH) Pulse Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes